Navigation Links
ThromboGenics NV - Q3 2009 Business Update
Date:11/4/2009

process development for TB-403 production. ThromboGenics received EUR3 million of the overall EUR5 million success fee.

Corporate Update

ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at the Scrip Awards 2009

    - In September 2009, ThromboGenics was shortlisted for "Biotech
      Company of the Year" and "Licensing Deal of the Year" at the Scrip
      Awards 2009. The Biotech Company of the Year award recognizes the
      progress and achievement a biotech company has made within the last
      twelve months. The Licensing Deal of the Year award acknowledges the
      achievement of a Company in signing a licensing deal that has both
      monetary and strategic benefits to all parties. The awards ceremony
      will take place on November 18, 2009 in London.

    - In October 2009, ThromboGenics announced that it raised
      EUR0.6 million as the result of the exercise of warrants. 90.000 shares
      were created and are now listed on Euronext Brussels. As a result of
      this exercise of warrants, ThromboGenics has 26.417.789 shares
      outstanding.

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB)
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
2. ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
3. ThromboGenics NV Announces Business Update and Half Year Results 2009
4. ThromboGenics NV: Business Update
5. ThromboGenics Announces Business Update and 2008 Full Year Results
6. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
7. ThromboGenics N.V.: Business Update
8. ThromboGenics Announces Half Year Results 2008
9. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
10. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015  AmnioChor Inc., an ... technology, is very pleased to announce that the Musculoskeletal ... has agreed to invest in their seed round of ... placental tissue storage capabilities. AmnioChor,s technology ... and the human stem cells living within those tissues. ...
(Date:7/29/2015)... -- Pfenex Inc. (NYSE MKT: PFNX) announced today that its ... Thursday, August 13, 2015, before the open of market.  ... a conference call to discuss the financial results and ... financial results and business update will be publicly distributed ... (US) or 1-412-542-4131 (international) and reference Pfenex to access ...
(Date:7/29/2015)... ... ... The third Medical Innovation Impact Index (MI3) Alert considers FDA processes for the ... system received a score of 0 (range -10 to +10) for its impact on ... Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. Several changes to ...
(Date:7/29/2015)... 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... selected an optimized Erk inhibitor molecule for development, ... of a new class of potential cancer therapies. ... prime target for therapeutic intervention in cancer. Recently ... benefits for B-Raf and Mek inhibitors. Erk inhibitors ...
Breaking Biology Technology:The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... Colo., Nov. 10, 2010 Biodesix Inc. announced today ... equity financing, lead by existing investors. The Series C ... commercialization activities for the company,s first product VeriStrat®, a ... patients with non-small cell lung cancer (NSCLC). Existing shareholders ...
... 2010 Regenicin, Inc . (OTC Bulletin Board: WDST), ... therapies to restore the health of damaged tissues and organs, ... OTC Bulletin Board from "WDST" to "RGIN.OB" effective at the ... Regenicin CEO, Randall McCoy said the change in ticker ...
... 10, 2010 Syngenta and DuPont today announced that ... effective November 8, 2010. The transaction dissolves a joint ... Hi-Bred. It enables Syngenta and Pioneer to pursue independent ... genetics and biotechnology traits. Davor Pisk, ...
Cached Biology Technology:Biodesix Completes Series C Financing and Receives Grant 2Biodesix Completes Series C Financing and Receives Grant 3Syngenta and DuPont Announce Ownership Change at GreenLeaf Genetics 2Syngenta and DuPont Announce Ownership Change at GreenLeaf Genetics 3Syngenta and DuPont Announce Ownership Change at GreenLeaf Genetics 4
(Date:7/31/2015)... julio de 2015 La 10 th International ... medio de BGI del 22 al 25 de octubre de 2015 ... Este año, la conferencia celebra su décimo aniversario. Desde su ... una de las reuniones anuales más influyentes del mundo en ... más dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/31/2015)... 31. Juli 2015 Die 10. internationale Konferenz zu ... veranstaltet und findet vom 22. bis 25. Oktober ... statt. Die Konferenz feiert in ... 2006 ist die ICG weltweit zu einem der ... ist eines der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen ...
(Date:7/31/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD AND SYSTEM ... crypto-currencies such as Bitcoin into the consumer market of ... manage all payments.  The technology manages ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... MD September 20, 2007) Fifteen students mentored by ... were selected to receive the 2007ASPB Summer Undergraduate Research ... devote full-time effort to his or her research project ... also includes $500 to the mentor for lab supplies, ...
... SeniorLifes Institute for Aging Research (IFAR) have examined close ... aging to help determine which genes are responsible for ... HSL studies surveyed the entire human genome (all the ... association study (GWAS), to look for common genetic variations ...
... biologists at Tufts University has discovered a dark ... on by fireflies each summer. Using both laboratory ... of firefly courtship displays, the biologists have uncovered ... be published in the November 2007 issue of ...
Cached Biology News:ASPB announces Summer Undergraduate Research Fellowship 2007 recipients 2ASPB announces Summer Undergraduate Research Fellowship 2007 recipients 3Hebrew SeniorLife researchers search for aging, osteoporosis genes 2Biologists expose hidden costs of firefly flashes 2Biologists expose hidden costs of firefly flashes 3
... , CapSure HS and CapSure Macro LCM ... of populations of pure cells from tissue ... Microdissection., Ensure the Integrity of Microdissected ... CapSure LCM Caps have a patented transfer ...
Opticon continuous fluorescence detector; includes optical base, analysis software, computer and monitor (this is an accessory for the DNA Engine thermal cyclers which must be ordered seperately)...
... on one plate. The new ArraySlide 96 ... (7mm x 7mm) individual printing surfaces for ... analysis studies. Unlike other systems, this device ... presence of contaminating adhesives. The chamber itself ...
... chambers for sealing hybridization reactions on slides. The ... on a glass slide. Reaction solution is added ... are then sealed with plastic sealing dots. Dots ... of reaction fluid. These chambers enclose a 20 ...
Biology Products: